['\xe2\x86\x91\xc2\xa0\xc2\xa0INDICATES INCREASE.', '\xe2\x86\x93\xc2\xa0\xc2\xa0INDICATES DECREASE.', 'A ONLY IF OTHER DRUGS ARE NOT AVAILABLE AND IF CLEARLY INDICATED. IF TREATMENT WITH LIFE-SUSTAINING DRUGS THAT CAUSE PANCREATIC TOXICITY IS REQUIRED, SUSPENSION OF VIDEX IS RECOMMENDED [ SEE WARNINGS AND PRECAUTIONS (5.1) ].', 'B [ SEE WARNINGS AND PRECAUTIONS (5.6) .]', 'DRUGS THAT MAY CAUSE PANCREATIC TOXICITY', '\xe2\x86\x91\xc2\xa0RISK OF PANCREATITIS', 'USE ONLY WITH EXTREME CAUTION A', 'NEUROTOXIC DRUGS', '\xe2\x86\x91\xc2\xa0RISK OF NEUROPATHY', 'USE WITH CAUTION B', 'ANTACIDS CONTAINING MAGNESIUM OR ALUMINUM', '\xe2\x86\x91\xc2\xa0SIDE EFFECTS ASSOCIATED WITH ANTACID COMPONENTS', 'USE CAUTION WITH VIDEX PEDIATRIC POWDER FOR ORAL SOLUTION', 'AZOLE ANTIFUNGALS', '\xe2\x86\x93\xc2\xa0KETOCONAZOLE OR ITRACONAZOLE CONCENTRATION', 'ADMINISTER DRUGS SUCH AS KETOCONAZOLE OR ITRACONAZOLE AT LEAST 2\xc2\xa0HOURS BEFORE VIDEX.', 'QUINOLONE ANTIBIOTICS (SEE ALSO CIPROFLOXACIN IN TABLE 8 )', '\xe2\x86\x93\xc2\xa0QUINOLONE CONCENTRATION', 'CONSULT PACKAGE INSERT OF THE QUINOLONE.', 'TETRACYCLINE ANTIBIOTICS', '\xe2\x86\x93\xc2\xa0ANTIBIOTIC CONCENTRATION', 'CONSULT PACKAGE INSERT OF THE TETRACYCLINE.']D FOR ADEQUATE CLINICAL RESPONSE WHEN VIDEX EC IS COADMINISTERED WITH METHADONE, INCLUDING MONITORING FOR CHANGES IN HIV RNA VIRAL LOAD.', 'NELFINAVIR', 'NO INTERACTION 1 HOUR AFTER DIDANOSINE', 'ADMINISTER NELFINAVIR 1 HOUR AFTER VIDEX.', 'TENOFOVIR DISOPROXIL FUMARATE', '\xe2\x86\x91\xc2\xa0DIDANOSINE CONCENTRATION', 'A DOSE REDUCTION OF VIDEX TO THE FOLLOWING DOSAGE ONCE DAILY IS RECOMMENDED. A 250 MG (ADULTS WEIGHING AT LEAST 60 KG WITH CREATININE CLEARANCE OF AT LEAST 60 ML/MIN) 200 MG (ADULTS WEIGHING LESS THAN 60 KG WITH CREATININE CLEARANCE OF AT LEAST 60\xc2\xa0ML/MIN) VIDEX AND TENOFOVIR DISOPROXIL FUMARATE MAY BE TAKEN TOGETHER IN THE FASTED STATE. IF TENOFOVIR DISOPROXIL FUMARATE IS TAKEN WITH FOOD, VIDEX SHOULD BE TAKEN ON AN EMPTY STOMACH (AT LEAST 30\xc2\xa0MINUTES BEFORE FOOD OR 2\xc2\xa0HOURS AFTER FOOD). PATIENTS SHOULD BE MONITORED FOR DIDANOSINE-ASSOCIATED TOXICITIES AND CLINICAL RESPONSE.']